Form 4: Nuvalent CFO Exercises Options, Sells Shares
Insider Transaction Report
Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, exercised stock options and subsequently sold a portion of her Class A Common Stock shares under a pre-arranged 10b5-1 trading plan.
Summary
- Nuvalent, Inc.'s Chief Financial Officer, Alexandra Balcom, reported transactions involving Class A Common Stock on November 17 and 18, 2025.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
- On November 17, 2025, Balcom acquired 6,875 shares by exercising options at $6.89 per share and 13,125 shares by exercising options at $72.35 per share.
- On the same day, she sold a total of 20,000 shares across multiple transactions at weighted average prices ranging from $93.80 to $103.68.
- On November 18, 2025, Balcom acquired 729 shares by exercising options at $72.35 per share and sold a total of 729 shares at weighted average prices ranging from $103.61 to $104.54.
- Following these transactions, Balcom directly beneficially owned 61,734 shares of Class A Common Stock.
- Remaining derivative securities include stock options to buy 29,101 shares at $6.89 and 33,646 shares at $72.35.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions (option exercises and sales) under a pre-arranged 10b5-1 plan, which is a neutral event for company sentiment.
Positives
- The exercise of stock options indicates the reporting person is realizing value from their compensation, which can be a positive sign of long-term commitment or belief in the company's value.
- Shares were sold at significantly higher prices than their exercise costs, indicating a profitable transaction for the insider. For example, options exercised at $6.89 and $72.35 were sold at prices up to $104.54.
Negatives
- The sale of a significant number of shares by a Chief Financial Officer, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence, although it is a common practice for liquidity and diversification.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider trading activities.
Industry Context
This Form 4 filing reports routine insider transactions and does not provide information relevant to broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even under a pre-arranged plan, might be viewed with slight caution, though it is a common practice for personal financial planning. The transactions are transparently disclosed.
- Employees: No direct impact on employees is indicated by this filing.
- Customers: No direct impact on customers is indicated by this filing.
- Suppliers: No direct impact on suppliers is indicated by this filing.
- Creditors: No direct impact on creditors is indicated by this filing.
Next Steps
- Continued vesting of remaining stock options, subject to continued service to Nuvalent, Inc. through the applicable vesting dates.
Key Dates
| Date | Description |
|---|---|
| 2022-04-29 | Initial vesting date for a portion of stock options with an exercise price of $6.89. |
| 2024-01-05 | Start of vesting period for stock options with an exercise price of $72.35, vesting over four years. |
| 2024-12-12 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2025-11-17 | Date of multiple transactions including option exercises and sales of Class A Common Stock. |
| 2025-11-18 | Date of additional transactions including option exercises and sales of Class A Common Stock. |
| 2025-11-19 | Date the Form 4 was signed by the attorney-in-fact. |
| 2031-04-29 | Expiration date for stock options with an exercise price of $6.89. |
| 2034-01-05 | Expiration date for stock options with an exercise price of $72.35. |
Keywords
Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, CFO, Share Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.